Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Shenzhen Hepalink Pharmaceutical Group Co Ltd (Hepalink) is a biopharmaceutical company that manufactures and distributes pharmaceutical active pharmaceutical ingredients (APIs) and products. The company carries out research, development and commercialization of innovative drugs. Its pipeline products including Oregovomab for primary advanced ovarian cancer and pancreatic cancer; AR20.5 which treats pancreatic cancer; Tosatoxumab (AR-301）targeting ventilator-associated pneumonia due to s. aureus infection; AR-101 for the treatment of ventilator-associated pneumonia; Apabetalone (RVX-208) treats reduction of major adverse cardiovascular events, diabetic nephropathy and fabry disease; and H1710 targets solid tumors. Hepalink is headquartered in Shenzhen, Guangdong, China.
Headquarters
China
Address
No. 21, Langshan Road, Songpingshan, Nanshan District, Shenzhen, Guangdong, 518057
Website
www.hepalink.com
No of Employees
2,150
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
002399 (SHE)
Revenue (2024)
$762.4M
3.8%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-46%
(2024 vs 2023)
Market Cap*
$1.9B
Net Profit Margin (2024)
XYZ
-47.9%
(2024 vs 2023)
* As of and is in US$
Shenzhen Hepalink Pharmaceutical Group Co Ltd premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| Pipeline | Contract Development and Manufacturing Organization (CDMO) Services |
| Oregovomab: Primary Advanced Ovarian Cancer and Pancreatic Cancer | |
| AR20.5: Pancreatic Cancer | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In January, the company partnered with Zhejiang Yongtai Pharmaceutical to distribute Gabapentin capsules in the US market. |
| 2023 | Contracts/Agreements | In March, OncoVent entered into a license agreement with Orient EuroPharma Co for the commercialization of oregovomab in Taiwan. |
| 2022 | Contracts/Agreements | In May, Cytovance Biologics and Avantor entered into a partnership, under which Avantor will strength Saiwan Biotech's cGMP plasmid production capabilities. |
Competitor Comparison
| Key Parameters | Shenzhen Hepalink Pharmaceutical Group Co Ltd | Shanghai Fosun Pharmaceutical (Group) Co Ltd | Livzon Pharmaceutical Group Inc | Zhejiang Hisun Pharmaceutical Co Ltd | Beijing Tiantan Biological Products Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Shenzhen | Shanghai | Zhuhai | Taizhou | Beijing |
| State/Province | Guangdong | Shanghai | Guangdong | Zhejiang | Beijing |
| No. of Employees | 2,150 | 40,603 | 8,878 | 8,751 | 5,205 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Li Li | Chairman | Executive Board | 2007 | 61 |
| Li Tan | Deputy general Manager; Director | Executive Board | 2007 | 61 |
| Chen Juan | Director - Finance | Senior Management | - | - |
| Qian Fengqi | Secretary | Senior Management | 2021 | 40 |
| Zhang Ping | Director | Non Executive Board | 2023 | 60 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer